Quan, Q.; Wang, Y.; Wang, F.; Zhang, D.; Chen, X.; He, W.; Zhang, B.; Guo, G.
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Curr. Oncol. 2021, 28, 209-219.
https://doi.org/10.3390/curroncol28010023
AMA Style
Quan Q, Wang Y, Wang F, Zhang D, Chen X, He W, Zhang B, Guo G.
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Current Oncology. 2021; 28(1):209-219.
https://doi.org/10.3390/curroncol28010023
Chicago/Turabian Style
Quan, Qi, Yixing Wang, Fenghua Wang, Dongsheng Zhang, Xiuxing Chen, Wenzhuo He, Bei Zhang, and Guifang Guo.
2021. "Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution" Current Oncology 28, no. 1: 209-219.
https://doi.org/10.3390/curroncol28010023
APA Style
Quan, Q., Wang, Y., Wang, F., Zhang, D., Chen, X., He, W., Zhang, B., & Guo, G.
(2021). Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Current Oncology, 28(1), 209-219.
https://doi.org/10.3390/curroncol28010023
